ICJIM

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics.

EndNote Style
Index
Original Article
Evaluation of the association between thyroid hormone levels and coronary slow flow in euthyroid patients: a retrospective study
Aims: Coronary slow flow (CSF) is an angiographic phenomenon characterized by delayed distal opacification of coronary arteries despite the absence of obstructive lesions. Although thyroid hormones are known to modulate cardiovascular hemodynamics, their potential association with CSF remains uncertain.
Methods: This retrospective, single-center, observational study included 170 patients (85 with angiographically confirmed CSF and 85 with normal coronary flow). Patients with overt thyroid dysfunction were excluded. Demographic, clinical, and biochemical characteristics were compared between the groups. Thyroid-related parameters (TSH, FT3, FT4, and FT4/FT3 ratio) were analyzed using receiver operating characteristic (ROC) curves and logistic regression to determine their discriminative and independent predictive value for CSF.
Results: Patients with CSF were significantly younger (49.3±10.0 vs. 54.8±11.1 years, p<0.001), predominantly male (72.9% vs. 47.1%, p=0.001), and more frequently smokers (59.0% vs. 36.9%, p=0.021) compared with controls. In multivariable logistic regression analysis, only age remained an independent predictor of CSF (OR 0.95, 95% CI 0.92-0.98, p=0.002). None of the thyroid parameters, including the FT4/FT3 ratio, demonstrated significant discriminative ability for CSF in ROC curve analysis (all AUC <0.60, p>0.05).
Conclusion: In euthyroid individuals, thyroid hormone levels and their ratios were not independently associated with coronary slow flow, whereas younger age and smoking emerged as stronger correlates. These findings suggest that routine thyroid hormone evaluation may not offer additional diagnostic or prognostic value in CSF.


1. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93(5):879-888. doi:10.1161/01.CIR.93.5.879
2. Hawkins BM, Stavrakis S, Rousan TA, Abu-Fadel M, Schechter E. Coronary slow flow-prevalence and clinical correlations. Circ J. 2012; 76(4):936-942. doi:10.1253/circj.CJ-11-0959
3. Mangieri E, Macchiarelli G, Ciavolella M, et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn. 1996;37(4):375-381. doi:10.1002/(SICI)1097-0304(199604)37:4<375::AID-CCD6>3.0.CO;2-8
4. Pekdemir H, Cin VG, Cicek D, et al. Slow coronary flow may be a sign of diffuse atherosclerosis: contribution of FFR and IVUS. Acta Cardiol. 2004;59(2):127-133. doi:10.2143/AC.59.2.2005166
5. Wang X, Nie SP. The coronary slow flow phenomenon: characteristics, mechanisms and implications. Cardiovasc Diagn Ther. 2011;1(1):37-43. doi:10.3978/j.issn.2223-3652.2011.10.01
6. Saya S, Hennebry TA, Lozano P, Lazzara R, Schechter E. Coronary slow flow phenomenon and risk for sudden cardiac death due to ventricular arrhythmias: a case report and review of literature. Clin Cardiol. 2008; 31(8):352-355. doi:10.1002/clc.20266
7. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15): 1725-1735. doi:10.1161/CIRCULATIONAHA.106.678326
8. Biondi B, Cooper DS. Subclinical hyperthyroidism. N Engl J Med. 2018; 378(25):2411-2419. doi:10.1056/NEJMcp1709318
9. Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol. 2017;14(1):39-55. doi:10.1038/nrcardio.2016.174
10. Yamakawa H, Kato TS, Yoshimura Noh J, et al. Thyroid hormone plays an important role in cardiac function: from bench to bedside. Front Physiol. 2021;12:606931. doi:10.3389/fphys.2021.606931
11. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev. 2005;26(5):704-728. doi:10.1210/er.2003-0033
12. Evrengul H, Tanriverdi H, Kose S, et al. The relationship between heart rate recovery and heart rate variability in coronary artery disease. Ann Noninvasive Electrocardiol. 2006;11(2):154-162. doi:10.1111/j.1542-474X. 2006.00097.x
13. Chen X, Zhang A, Xu Z, et al. Analysis of correlative factors of female coronary slow-flow phenomenon: a retrospective study. Medicine (Baltimore). 2024;103(21):e38262. doi:10.1097/MD.0000000000038262
14. Madak N, Nazli Y, Mergen H, et al. Acute phase reactants in patients with coronary slow flow phenomenon. Anatol J Cardiol. 2010;10(5):416-420. doi:10.5152/akd.2010.139
15. Aparicio A, Cuevas J, Morís C, Martín M. Slow coronary blood flow: pathogenesis and clinical implications. Eur Cardiol. 2022;17:e08. doi:10. 15420/ecr.2021.46
16. Sezgin AT, Sigirci A, Barutcu I, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis. 2003;14(2):155-161. doi:10.1097/00019501-200304000-00008
17. Ahmed KA, Syed W, Ahmed JA, et al. Coronary slow flow phenomenon: a narrative literature review. Cureus. 2025;17(7):e88657. doi:10.7759/cureus.88657
18. Kopetz V, Kennedy J, Heresztyn T, Stafford I, Willoughby SR, Beltrame JF. Endothelial function, oxidative stress and inflammatory studies in chronic coronary slow flow phenomenon patients. Cardiology. 2012;121: 197-203. doi:10.1159/000336948
19. Razvi S, Jabbar A, Pingitore A, et al. Thyroid hormones and cardiovascular function and diseases. J Am Coll Cardiol. 2018;71(16):1781-1796. doi:10. 1016/j.jacc.2018.02.045
20. Vargas-Uricoechea H, Sierra-Torres CH. Thyroid hormones and the heart. Horm Mol Biol Clin Investig. 2014;18(1):15-26. doi:10.1515/hmbci- 2013-0059
21. Kaplangoray M, Toprak K, Deveci E, Caglayan C, Şahin E. Could pan-immune-inflammation value be a marker for the diagnosis of coronary slow flow phenomenon? Cardiovasc Toxicol. 2024;24(5):519-526. doi:10. 1007/s12012-024-09855-4
22. Akkaya S, Cakmak U. Association between pan-immune-inflammation value and coronary slow flow phenomenon in patients with angiographically normal coronary arteries. Int J Cardiol. 2024;398: 131631. doi:10.1016/j.ijcard.2023.131631
23. MozafaryBazargany M, Khalili Pour E, Shamsedini A, et al. Chorioretinal microvascular changes in slow flow coronary phenomenon: a multi-center study. Sci Rep. 2024;14(1):31090. doi:10.1038/s41598-024-82118-y
24. Tian L, Zhang L, Liu J, et al. Effects of TSH on the function of human umbilical vein endothelial cells. J Mol Endocrinol. 2014;52(2):215-222. doi:10.1530/JME-13-0119 </ol> <p>
Volume 3, Issue 4, 2025
Page : 73-76
_Footer